ÇERKEZKÖY-2
DEVA Holding Çerkezköy-II Manufacturing Facility, which has enclosed facilities of 50,270 m2 established on an area of 67,551 m2 in Çerkezköy Organized Industrial Zone, at a distance of approximately 110 km from Istanbul, is made up of modern buildings manufacturing solid oncology products, sterile liquid oncology products, animal health products and APIs.
Çerkezköy-II Manufacturing Facility also houses the Biotechnology Building, the Central Stability Building, and the R&D Center Buildings, each dedicated to their respective fields of operation.
Solid Oncology Manufacturing Unit
Products in the form of tablets and capsules are manufactured in the Solid Oncology Manufacturing Unit.
The total quantity manufactured, which was 1.84 million units in 2023, increased by 8% to 1.99 million units in 2024.
Of the total 1.99 million units manufactured in 2024, 1.29 million units were tablets, and 0.70 million units were capsules.
Additionally, of the 1.29 million tablet units manufactured, 0.40 million units were produced for the European market, while 0.42 million units of the 0.70 million capsules were also manufactured for the European market.
Sterile Liquid Oncology Manufacturing Unit
Products in the form of sterile liquid and sterile lyophilized powder are manufactured in the Sterile Liquid Oncology Manufacturing Unit.
The total quantity manufactured in the unit, which was 0.58 million units in 2023, reached 0.77 million units in 2024.
Of the 0.77 million units manufactured, 0.59 million units were liquid products, while 0.18 million units were lyophilized products.
Non-Sterile (Solid) Animal Health Products Manufacturing Unit
Animal health products are manufactured in the NonSterile (Solid) Animal Health Products Manufacturing Unit, 7 of which are in tablet form, 11 in powder form filled in small and large sachets.
The total quantity manufactured in the unit, which was 0.32 million units in 2023, reached 2.11 million units in 2024. Of these products, 2.01 million units were tablets, while 0.10 million units were in powder form.
API (Active Pharmaceutical Ingredient) Manufacturing Units
The facility has two physically separate and independent API Manufacturing Units for manufacture of non-betalactam API and oncolytic API.
The total quantity of API manufactured, which was 3,142 kg in 2023, reached 2,651 kg in 2024.
Of the total 2,651 kg of API manufactured in 2024, 1,746 kg was non-betalactam, while 905 kg was oncologic API.
In API manufacturing, the toxic gases arising from reaction are neutralized before being released to the atmosphere to minimize the environmental effects resulting from manufacturing activities.
In summary, the total quantity of finished products manufactured at DEVA Holding’s Çerkezköy-II Facility was 2.74 million units in 2023, increasing to 4.87 million units in 2024.
The total capacity utilization rate at our Çerkezköy Manufacturing Facilities is 90%.
